AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04193540 — intervention group
Intervention type: OTHER
Intervention: ACE questionnaire
Description: Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
Study NCT01533818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0
Study NCT01533818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Syrup
Description: It will be given 2 times/day for 7 days
Study NCT01164618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
Study NCT01164618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
Study NCT04221672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin plus standard care
Description: All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.
Study NCT04221672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: All the participants received routine care after surgery only.
Study NCT04265352 — intervention group
Intervention type: OTHER
Intervention: No intervension
Description: There is intervention at all.
Study NCT00981877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB (Florestor)
Description: S. Boulardii preparation of 1 gram twice daily for 5 days
Study NCT00981877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRALB
Description: mixed probiotic preparation 1 gram twice daily for 5 days.
Study NCT00981877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GC (placebo)
Description: Placebo 1 gram twice daily for 5 days.
Study NCT01720160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO® System
Description: Implant procedure
Study NCT01720160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care medical managment therapy for heart failure
Description: Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
Study NCT01720160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medical managment therapy for heart failure
Description: Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
Study NCT03992391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Prevention Intensive Outpatient Program
Description: participation in a suicide prevention intensive outpatient program
Study NCT03179735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study NCT03179735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride 0.7 mg/ml
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study NCT03179735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding.
Study NCT00989222 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: closed reduction and external fixation
Description: Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
Study NCT00989222 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation with a volar locked plate
Description: Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
Study NCT02175225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Mesylate
Study NCT02175225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Deferoxamine Mesylate)
Study NCT04028362 — intervention group
Intervention type: DRUG
Intervention: Neuromuscular Blocking Agents
Description: Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02743364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02743364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study NCT01753609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip capsule
Description: swallowing Tulip capsule for up to 29 days
Study NCT04309032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde bladder filling with 0.9% normal saline 250cc prior to removal of foley catheter
Description: 0.9% NS 250cc was introduced before foley catheter removed for discharge
Study NCT03017222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
Study NCT03017222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
Study NCT04693429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate
Description: Bepotastine Besilate 1.5% QID (quater in die) for 7 days
Study NCT03513016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection
Study NCT03513016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent intra-articular injection
Study NCT04308863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan scaffold/ MTA pulp dressing material
Description: Chitosan 3-D porous scaffold will be prepared. The chitosan scaffolds will be examined with the Scanning electron microscopy (SEM) to analyze the surface of the chitosan scaffolds. The scaffolds will be sterilized by Ethylene oxide and stored until further use. A piece of 2-mm thick chitosan scaffold will be gently placed onto the pulp chamber floor and covering the canal orifices, and then a 2-3 mm thick layer of fast setting EndoCem Zr MTA will be applied onto the chitosan scaffold and will be gently condensed with moistened cotton pellet to attain adequate thickness which will be confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Study NCT04308863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulp dressing material
Description: MTA will be gently placed over the fresh pulp wound using an MTA carrier to a thickness of 2-3 mm. It will be condensed lightly with moistened cotton pellet to attain adequate thickness and confirmed radiographically. MTA will be allowed to set for 4-5 mins.
Study NCT01608880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin ointment
Description: Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
Study NCT01608880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polysporin ointment
Description: Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
Study NCT02322749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 blue capsules of 25 mg given as a single dose
Study NCT02322749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 capsules of 25 mg given as a single dose
Study NCT01259947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lippia alba (Mill.) N. E. Brown ethanolic extract
Description: 1-2 drops per kilogram per day, PO, twice a day
Study NCT02164955 — intervention group
Intervention type: DRUG
Intervention: IMNOVID
Description: IMNOVID (pomalidomide) as prescribed in routine clinical practice
Study NCT00952666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUS-RALRP
Description: During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
Study NCT02852421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single injection paravertebral block
Description: The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections
Study NCT02852421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple injection paravertebral blocks
Description: Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level.
Study NCT01331317 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paricalcitol
Description: capsule, 1-2 micrograms daily for 90 days
Study NCT02974933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib combined with pemetrexed
Description: For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
Study NCT02374320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: injected as an axillary block
Study NCT02391051 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR-Brachytherapy
Description: HDR-Brachytherapy 2x 13,5 Gy
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Antileukemic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Growth factor
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Antileukemic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teniposide
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CNS irradiation
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mediastinal Irradiation
Description: Irradiation
Study NCT00198991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Description: Stem cell transplantation
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cytostatic drug
Study NCT00198991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cytostatic drug
Study NCT01093846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 300mg every 4 weeks
Study NCT01093846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 300mg every 2 weeks
Study NCT01093846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AIN457
Description: Placebo to AIN457
Study NCT04601740 — intervention group
Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT02615886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observational Control
Description: Participants will be observed and not provided any dietary supplementation.
Study NCT02615886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice bran
Description: Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
Study NCT04481139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302, oral, once daily
Study NCT01853475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQP tablets 960mg
Description: Piperaquine phosphate tablets 960mg
Study NCT04481139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo
Description: SHR0302 placebo, oral, once daily
Study NCT06259214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15% HCl gel
Description: Icon , DMG, Hamburg, Germany
Study NCT06259214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: H3PO4 gel
Description: Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
Study NCT06259214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG laser
Description: Fotona AT Fidelis III, Ljubljana, Slovenia
Study NCT04416997 — intervention group
Intervention type: PROCEDURE
Intervention: Blood and serum samples
Description: The blood and serum samples will taken from RA patients
Study NCT02449421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Learning Community
Description: Consultation with CPT experts to effectively use evidence-based psychotherapy.
Study NCT02449421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fidelity-oriented Learning Community
Description: The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
Study NCT02939209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hcl 2Mg Tab
Description: Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
Study NCT02939209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients may be randomized to placebo.
Study NCT04780815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 1
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
Study NCT04780815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myBluTM Formulation 2
Description: 1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
Study NCT03025113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen and cyclobenzaprine association
Description: The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
Study NCT03025113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
Study NCT02232204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia in ICD Patients (CBT-I-ICD)
Description: Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.